Drug Selection and Dosage in Renal Insufficiency

  • Jean Fabre
  • Irving Ohr
Part of the Ergebnisse der Inneren Medizin und Kinderheilkunde. Neue Folge Advances in Internal Medicine and Pediatrics book series (KINDERHEILK. NF, volume 34)


Patients with renal insufficiency often react abnormally to a number of drugs. Small doses that are perfectly safe under normal conditions may cause severe and even fatal side effects. Too frequently, these untoward reactions are confused with the symptomatology of uremia and their real cause remains unrecognized.


Creatinine Clearance Renal Insufficiency Normal Renal Function Drug Selection Uremic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alano, F. A., Webster, G.D.: Acute renal failure and pigmentation due to phenazopyridine (Pyridium). Ann. intern. Med. 72, 89–91 (1970).PubMedGoogle Scholar
  2. ALEXANDER, W.D., EVANS, V., MACAULAY, A., GALLAGHER, T.F., LONDONS, J.: Metabolism of 35S–labeled antithyroid drugs in man. Brit. med. J. 1969II, 290–291.Google Scholar
  3. ALPEN, E.L., MANDEL, H.G., RODWELL, V.W., SMITH, P. K.: The metabolism of 14C carboxyl salicylic acid in the dog and in man. J. Pharmacol, exp. Ther. 102, 150–155 (1951).Google Scholar
  4. ANEX, L., FAVEZ, G., WILLA, C.: Comparaison entre les clearances rénales à l’inuline et au para–amino–hippurate et les concentrations sanguines d’éthambutol. Schweiz. med. Wschr. 102, 126–128 (1972).Google Scholar
  5. ASATOOR, A.M., LONDON, D.R., MILNE, M. D., Simenhoff, M.L.: The excretion of pethidine and its derivatives. Brit. J. Pharmacol. 20, 285–298 (1963).PubMedGoogle Scholar
  6. ATUK, N.O., MOSCA, A., Kunin, C.: The use of potentially nephrotoxic antibiotics in the treatment of Gram–negative infections in uremic patients. Ann. intern. Med. 60, 28–38 (1964).PubMedGoogle Scholar
  7. AVIOLI, L.V., BIRGE, S., LEE, S.W., SLATOPOLSKY, E.: The metabolic fate of vitamin D3–3H in chronic renal failure. J. clin. Invest. 47, 2239–2252 (1968).PubMedCrossRefGoogle Scholar
  8. AZZOLINI, F., GAZZANIGA, A., LODOLA, E.: Thiophenicol excretion in subjects with renal insufficiency. Int. J. Pharmacol, ther. Toxicol. 34, 303–308 (1970).Google Scholar
  9. BAADT, A., CORBIN, E.E., PRIGOT, A.: Observations on the absorption, diffusion and excretion of oleandomycin in human beings. Antibiot. Ann. 72–74 (1956–1957).Google Scholar
  10. BACH, J. F., DARDENNE, M.: The metabolism of azathioprine in renal failure. Transplantation 12, 253–259 (1971).PubMedCrossRefGoogle Scholar
  11. BAETHKE, R., GOLDE, G., GAHL, G.: Sulphamethoxazole/Trimethoprim: Pharmacokinetic studies in patients with chronic renal failure. Europ. J. clin. Pharmacol. 4, 233–240 (1972)CrossRefGoogle Scholar
  12. BALANT, L., ZAHND, G., GORGIA, A., SCHWARZ, R., FABRE, J.: Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia Suppl. to 9, 331–338 (1973).CrossRefGoogle Scholar
  13. BATES, J. H., SCHULTZ, J. C., ABGRANATHY, R. S.: Kanamycin administration in patients with impaired renal function. Clin. Res. 13, 77–82 (1965).Google Scholar
  14. BAUR, M.: Zur Pharmakologie des Harnstoffs (Beiträge zum Problem der Urämie). Arch, exp. Path. Pharmakol. 167, 104–114 (1932).Google Scholar
  15. BECKMANN, R.: The fate of biguanides in man. Ann. N.Y. Acad. Sei. 148, 820–832 (1968).CrossRefGoogle Scholar
  16. BENNETT, W.M., SINGER, I., COGGINS, C.H.: A practical guide to drug usage in adult patients with impaired renal function. J. Amer. med. Ass. 214, 1468–1475 (1970).CrossRefGoogle Scholar
  17. BERENBAUM, M.C.: Immunosuppressive agents and allogenic renal transplantation. J. clin. Path. 20, 471–498 (1968).Google Scholar
  18. BERGER, W.: Achtundachtzig schwere Hypoglykämiezwischenfälle unter der Behandlung mit Sulfonylharnstoff. Schweiz, med. Wschr. 71, 1013–1022 (1971).Google Scholar
  19. BERNARD, B., YIN, E.J., SIMON, H.J.: Clinical pharmacologic studies with minocycline. J. clin. Pharmacol. 11, 332–348 (1971).Google Scholar
  20. BEYER, K.H., BAER, J.E., MICHAELSON, J.K., RUSSO, H.F.: Renotropic caracteristics of ethacrynic acid, a phenoxyacetic saluretic-diuretic agent. J. Pharmacol, exp. Ther. 147, 1–22 (1965).Google Scholar
  21. BLOOM, P.M., NELP, W.P.: Relationship of the excretion of tritiated digoxin to renal function. Amer. J. med. Sei. 251, 133–144 (1966).CrossRefGoogle Scholar
  22. BOISSIER, J.R., SIMON, P., LWOFF, J.M., BRETEAU, M.: Action d’un sulfamide diurétique (Clopamide) chez le rat en insuffisance rénale chronique expérimentale. Thérapie 20, 393–399 (1965).PubMedGoogle Scholar
  23. BOLT, W., von RITZL, F., TOUSSAINT, R., NAHRMANN, H.: Verteilung und Ausscheidung eines cytostatisch Wirkenden mit Tritium markierendem N-Lost-Derivatives beim Krebskranken Menschen. Arzneim.-Forsch. 11, 170–175 (1961).Google Scholar
  24. BOVET, D., BOVET-NITTI, F., GUARINO, S., LONGO, V. G., FUSCO, R.: Recherches sur les poisons curarisants de synthèse. III. Succinylcholine et dérivés aliphatiques. Arch. int. Pharmacodyn. 88, 1–50 (1951).Google Scholar
  25. BRASS, H.: Zur Therapie mit Herzglycosiden bei Patienten mit Niereninsuffizienz. Dtsch. med. Wschr. 95, 754–758 (1970).Google Scholar
  26. BRETTELL, H. R., AIKAWA, J.K., GORDON, G.S.: Studies with chlorothiazide tagged with radioactive carbon (C14) in human beings. Arch, intern. Med. 106, 57–63 (1960).Google Scholar
  27. BRETTELL, H. R., SMITH, J. G., AIKAWA, J.K.: Clinical studies with S35 benzydroflumethiazide. Clin. Res. 11, 238 (abstr.) (1963).Google Scholar
  28. BRIDGMAN, J.F., ROSEN, S.M., THORP, J.M.: Complications during Clofibrate treatment of nephrotic syndrome hyperlipoproteinemia. Lancet 1972II, 506–509.Google Scholar
  29. BRODIE, B.B., ARONOW, L., AXELROD, J.: The fate of benzazoline (Priscolinal) in dog and man and a method for its estimation in biological material. J. Pharmacol, exp. Ther. 106, 200–207 (1952).Google Scholar
  30. BRODIE, B.B., BAER, J. E., CRAIG, L.C.: Metabolic products of the cinchona alkaloids in human urine. J. biol. Chem. 188, 576–580 (1951).Google Scholar
  31. BRODIE, B.B., BAEVEN, M.A.: Neurochemical transducer systems. Med. Exp. (Basle), 8, 320–351 (1963).Google Scholar
  32. BRODIE, B.B., LIEF, P. A., POET, R.: The fate of procaine in man following its intravenous administration and methods for the estimation of procaine and diethylamino-ethanol. J. Pharmacol, exp. Ther. 94, 359–366 (1948).Google Scholar
  33. BROUET, G., GODEAU, P., BERGOGNE, E.: Dosage de L’isoniazide libre dans le sérum sanguin dans le traitement de la tuberculose. Intérêt pratique. Thérapie 16, 393–410 (1961).Google Scholar
  34. BROUET, G., MARCHE, J.: Les complications d’ordre métabolique et endocrinien produites par la chimiothérapie antibacillaire. Rev. Tuberc. (Paris) 28, 5–76 (1964).Google Scholar
  35. BROWNLEE, G., BUSHBY, S. R., SHORT, E. I.: Chemotherapy and pharmacology of polymyxins. Brit. J. Pharmacol. 7, 170–188 (1952).PubMedGoogle Scholar
  36. BRUNNER, F. P., FRICK, F. G.: Hypokalemia, metabolic alkalosis, and hypernatremia due to “massive” sodium penicillin therapy. Brit. med. J. 1968IV, 550–552.Google Scholar
  37. BUHS, R. P., BECK, J. L., SPETH, O.C., SMITH, J. L., TRENNER, N.R., CANNON, P. J., LARAGH, J.H.: The metabolism of methyldopa in hypertensive human subjects. J. Pharmacol, exp. Ther. 143, 205–214 (1964).Google Scholar
  38. BULGER, R.J., LINDHOLM, D.D., MURRAY, J.S., KIRBY, W.M.M.: Effect of uremia on methicillin and oxacillin blood levels. J. amer. med. Ass. 187, 319–322 (1964).CrossRefGoogle Scholar
  39. BUNKER, J.B., BEECHER, H.K., BRIGGS, B.D., et al.: Metabolic effects of anesthesia. A comparison of acide-base equilibrium in man and in dog during ether and during cyclopropane anesthesis. J. Pharmacol, exp. Therap. 102, 62–70 (1951).Google Scholar
  40. BURCH, O., RAY, T., THREEFOOT, S., KELLY, E. J., SVEDBURG, A.: The urinary excretion and biologic decay periods of radiomercury labelling a mercurial diuretic in normal and diseased man. J. clin. Invest. 29, 1131–1138 (1950).PubMedCrossRefGoogle Scholar
  41. BURNETT, C.H., BLOOMBERG, E.L.: Comparison of effects of ether and cyclopropane anesthesia on renal function in man. J. Pharmacol, exp. Ther. 96, 380–387 (1949).Google Scholar
  42. BURNS, J. J., ROSE, R., GOODWIN, S., REICHENTHAL, J., HORNING, E.C., BRODIE, B.: The metabolic fate of phenylbutazone in man. J. Pharmacol, exp. Ther. 113, 481–489 (1955).Google Scholar
  43. BUTIKOFER, E., et al.: Über die Eliminierungsgeschwindigkeit von Glutethimid (Doriden) und die Natur der Ausscheidungsprodukte beim Mensch. Arch. exp. Path. Pharmakol. 244, 97–102 (1962).CrossRefGoogle Scholar
  44. BUTLER, T.C.: Quantitative studies of the demethylation of trimethadione (Tridione). J. Pharmacol, exp. Ther. 108, 11–17 (1953).Google Scholar
  45. BUTTNER, H., PORTWICK, F., MANZKE, R., STAUDT, N.: Zur Pharmakokinetik von Sulfonamiden unter pathologischen Bedingungen. Klin. Wschr. 42, 103–108 (1964).CrossRefGoogle Scholar
  46. CALABRESI, P.: Current status of clinical investigations with 6-azauridine, 5-iodo-2-deoxy- uridine, and related derivatives. Cancer Res. 23, 1260–1267 (1963).PubMedGoogle Scholar
  47. CAMERON, J.S., TOSELAND, P.A., READ, J.F.: Accumulation of barbitone in patients on regular hemodialysis. Lancet 1970I, 912–914.Google Scholar
  48. CARAPS, S., CODINA, A., CASTELLS, A.: Sindrome extrapyramidal por metoclopramide en enfermos con insuficiency renal avanzada. Rev. clin. esp. 123, 365–368 (1971).Google Scholar
  49. CASTAIGNE, J.: La perméabilité méningée dans l’urémie nerveuse. C. R. Soc. Biol. 52, 907–911 (1900).Google Scholar
  50. CAWTHORNE, T., RANGER, D.: Toxic effect of streptomycin upon balance and hearing. Brit, med. J. 1957I, 1444-1446.Google Scholar
  51. CHAN, R.A., BENNER, E. J., HOEPRICH, P.D.: Gentamicin therapy in renal failure: a normo- gram for dosage. Ann. intern. Med. 78, 773–778 (1972).Google Scholar
  52. CHARLES, M. A., DANFORTH, J.R.: Nonketoacidotic hyperglycemia and coma during intravenous diazoxide therapy in uremia. Diabetes 20, 501–503 (1971).PubMedGoogle Scholar
  53. CHAVAZ, A., BALANT, L., FABRE, J.: Digoxinémie et digitalisation. Schw. med. Wschr. 104, 65–74 (1974).Google Scholar
  54. CIMINO, J.E., TIERNO, P.M., Jr.: Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Appl. Microbiol. 17, 446–448 (1969).PubMedGoogle Scholar
  55. CLANE, R.Y.: Renal transplantation, p. 145. London: Arnold Publ. 1967.Google Scholar
  56. CLARKSON, B., O’CONNOR, A., WINSTON, L., HUTCHISON, D.: The physiologic disposition of 5-fluorouracil and 5-fluoro-2-deoxyuridine in man. Clin. Pharmacol. Ther. 5, 581–610 (1964).PubMedGoogle Scholar
  57. COHEN, B.D., GALLOWAY, J.A., MCMAHON, R.E.: Carbohydrate metabolism in uremia: blood glucose response to sulfonylurea. Amer. J. med. Sei. 254, 608–618 (1967).CrossRefGoogle Scholar
  58. COHEN, E.N., BREWER, H. W., SMITH, D.: The metabolism and elimination of d-tubo-curarine H3. Anesthesiology 28, 309–317 (1967).PubMedCrossRefGoogle Scholar
  59. COHN, E.S., GORDES, E.H., BRUSILOW, S. W.: Ethacrynic acid effect on the composition of cochlear fluids. Science 171, 910–911 (1971).PubMedCrossRefGoogle Scholar
  60. COTTIER, P., HALDEMANN, G.: De l’emploi d’un sulfamide (Ro 4-4393) à durée d’action prolongée dans le traitement de la pyélonéphrite chronique. J. Urol. Néphrol. 70, 797–809 (1964).Google Scholar
  61. COTTER, P., REUBI, F., DUPASQUIER, E.: Die Wirkung von Guanethidin auf den Hochdruck und die Nierenfunktion bei klinischer und ambulanter Behandlung. Dtsch. med. Wschr. 85, 1263–1271 (1960).Google Scholar
  62. CRANDELL, W.B., PAPPAS, S.G., MACDONALD, A.: Nephrotoxicity associated with methoxy- flurane anesthesis. Anesthesiology 27, 591–607 (1966).PubMedCrossRefGoogle Scholar
  63. Curtis, J.R., Eastwood, J.B.: Colistin sulfomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis. Brit. med. J. 1968I, 484-485.Google Scholar
  64. CUTRITS, J.R., MCDONALD, S. J., WESTON, J. H.: Parenteral administration of gentamicin in renal failure: patients undergoing intermittent haemodialysis. Brit. med. J. 1967II, 537–539.Google Scholar
  65. DAVIDSON, H.C.C., WAY, W.L., DEJONG, R.H.: The muscle relaxants and renal excretion. Anesthesiology 28, 540–546 (1967).Google Scholar
  66. DAYTON, P.G., SICAM, L.E., LANDRAU, M., BURNS, J.J.: Metabolism of sulfinpyrazone (Anturane) and other thio analogs of phenylbutazone in man. J. Pharmacol, exp. Ther. 132, 287–290 (1961).Google Scholar
  67. DAYTON, P.G., YU, T. F., CHEN, W., BERGER, L., WEST, L. A., GUTMAN, A.B.: The physiological disposition of probenecid. J. Pharmacol, exp. Ther. 140, 278–286 (1963).Google Scholar
  68. DENIZOT, M., FABRE, J., POMETTA, D., WILDI, E.: Nephrotic syndrome, Clofibrate and muscular pain. Lancet 1973II, 1326.Google Scholar
  69. DESJACQUES, P.: Etude de la diffusion de la diphénylhydantoîne à travers la membrane de cellophane du rein artificiel chez un malade urémique et épileptique. Praxis 61, 418–423 (1972).PubMedGoogle Scholar
  70. DESMONTS, J. M., MIGNON, F., HENNETIER, G., DIMARIA, G.: L’anesthésie au cours de l’insuffisance rénale aiguë. Anesth. Analg. Réanim. 25, 81 –92 (1968).Google Scholar
  71. DETTLI, L.: Dosierungstheorie für die repetierte Applikation reversibel wirkender Pharmaka bei Eliminationsinsuffizienz. In: Pharmacological and clinical Significance of Pharmacokinetics, Symposia Medica Hoechst, pp. 31–41. Stuttgart-New York: Schattauer 1970.Google Scholar
  72. DETTLI, L.: SPRING, P., RYTER, S.: Multiple dose kinetics and drug dosage in patients with kidney disease. In: Proc. Symposium on Biological and Pharmaceutical Aspects of Pharmacokinetics and Therapeutics, pp. 211–224. Copenhagen: Musgaard 1971.Google Scholar
  73. DEUTSCH, S., GOLDBERG, M., STEPHAN, G. W., WO, W.H.: The effect of halothane anesthesia on renal function in normal man. Anesthesiology 27, 793–804 (1966).PubMedCrossRefGoogle Scholar
  74. DIMMLING, T., LUTZEYER, W., HÜENER, H.: Resorption und Ausscheidung von Oxytetracyclin in Abhängigkeit von der Nierenfunktion der urologischen Kranken. Arzneim.-Forsch. 7, 681–684 (1957).Google Scholar
  75. DOHERTY, J.E.: The clinical pharmacology of digitalis glycosides: a review. Amer. J. med. Sei. 255, 382–414 (1968).CrossRefGoogle Scholar
  76. DOHERTY, J.E.: FLANIGAN, W. J.: Studies with tritiated digoxin in anephric human subjects. Circulation 35, 298–302 (1967).PubMedGoogle Scholar
  77. DOHERTY, J.E.: PERKINS, W.H., WILSON, M.C.: Studies with tritiated digoxin in renal failure. Amer. J. Med. 37, 536–543 (1964).PubMedCrossRefGoogle Scholar
  78. DOHERTY, C. T.: Methyl-dopa in hypertension. Amer. Heart J. 65, 139–140 (1963).CrossRefGoogle Scholar
  79. DOHERTY, C. T.: SMITH, D.E., MILNE, M.D.: Clinical and pharmacological studies with guanethidine in the treatment of hypertension. Lancet 1960II, 381–387.Google Scholar
  80. DOST, F.H.: Grundlagen der Pharmakokinetik. Stuttgart: Thieme 1968.Google Scholar
  81. DRING, J. G., SMITH, R.L., WILLIAMS, R. T.: The metabolic fate of amphetamine in man and other species. Biochem. J. 116, 425–435 (1970).PubMedGoogle Scholar
  82. DUBACH, U.C., BÜCKERT, A., FORGO, I., RENTSCH, G.: Etude pharmaco-clinique du glibornuride. Symposium international sur les agents hypoglycémiants. Evian 1971.Google Scholar
  83. DUBOIS-PRIMO, J., GEENS-BASTENIER, J., GENICOTT, C.: Anesthésie générale chez l’insuffisant rénal. Anesth. Anal. Réanim. 28, 343–354 (1969).Google Scholar
  84. DUNDEE, J.W., RICHARDS, R.K.: Effect of azotemia upon the action of intravenous barbiturate anesthesia. Anesthesiology 15, 333–346 (1954).PubMedCrossRefGoogle Scholar
  85. DUPONT, P., DUCKERT, A., FABRE, J.: Modifications du métabolisme électrolytique et des fonctions glomérulaires et tubulaires sous l’influence de dérivés pyrazolés. Helv. med. Acta 19, 528–546 (1952).Google Scholar
  86. EASTWOOD, J. B., CURTIS, J. R.: Carbenicillin administration in patients with severe renal failure. Brit. med. J. 1968I, 486–487 (1968).Google Scholar
  87. EDWARDS, K. D. G., WHYTE, H. M.: Streptomycin poisoning in renal failure. An indication for treatment with an artificial kidney. Brit. med. J. 1959I, 752–754.Google Scholar
  88. ELION, G.B.: Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed. Proc. 26, 898–904 (1967).PubMedGoogle Scholar
  89. ELION, G.B., Yu, T. F., GUTMAN, A.B., HITCHINGS, G. H.: Renal clearance of oxypurinol, the chief metabolite of allopurinol. Amer. J. Med. 45, 69–77 (1968).PubMedCrossRefGoogle Scholar
  90. FABRE, J.: Les oedèmes pyrazoliques. Sem. Hop. Paris 30, 444–447 (1954).PubMedGoogle Scholar
  91. FABRE, J.: Médicaments et fonctions rénales. Helv. med. Acta Suppl. 47, 24–41 (1967a).Google Scholar
  92. FABRE, J.: BALANT, L., ZAHND, G.: Comportement delà glipizide(sulfonylurée hypoglycémiante) dans l’insuffisance rénale. To be published in Le Diabète (1973a).Google Scholar
  93. FABRE, J.: DENIZOT, M., WILDI, E., MICHELI, H.: Pouvoir hypolipémiant et action myotoxique du Clofibrate en cas de syndrome néphrotique. Praxis 62, 732–737 (1973b).PubMedGoogle Scholar
  94. FABRE, J.: de Freudenreich, J., Duckert, A., Pitton, J. S., Rudhardt, M., Virieux, C.: Influence of renal insufficiency on the excretion of chloroquine, phénobarbital, phenothiazines and methacycline. Helv. med. Acta 33, 307–316 (1967 b).Google Scholar
  95. FABRE, J.: Leblanc, A.: La néphrotoxicité des médicaments. In: Heusghem, C., Lechat, P.: Effets indésirables des médicaments, p. 490. Paris: Masson 1973.Google Scholar
  96. FABRE, J.: MERIER, G., LAURENCET, F. L., RUDHARDT, M., Chuit, A.: Behaviour of doxycycline in renal insufficiency. Helv. med. Acta 35, 124–134 (1969).PubMedGoogle Scholar
  97. FABRE, J.: MILEK, E., KALFOPOULOS, P., MERIER, G.: La cinétique des tétracyclines chez l’homme. Schweiz, med. Wschr. 101, 593–598 and 625–633 (1971).Google Scholar
  98. FABRE, J.: PITTON, J. S., VIRIEUX, C., LAURENCET, F. L., BERNHARDT, J. P., GODEL, J. C.: Absorption, distribution et excrétion de la doxycycline chez l’homme. Schweiz, med. Wschr. 97, 915–924 (1967c).Google Scholar
  99. FALBRIARD, A., FABRE, J., ENGEL, E., DUCKERT-MAULBETSCH, A.: Les sulfamides inhibiteurs de la carboanhydrase et leur action rénale. Médecine dans le Monde 31, E7–E21 (1957).Google Scholar
  100. FALOON, W. W., DOWNS, J. J., DUGGAN, K., PRIOR, J. T.: Nitrogen and electrolyte metabolism and hepatic function and histology in patients receiving tetracycline. Amer. J. med. Sei. 233, 563–572 (1957).CrossRefGoogle Scholar
  101. FLOCK, E.V., BOLLMAN, J.L., GRINDLEY, J.H., OVIS, A.L.: Metabolism of L-thyroxine and L-triiodothyrosine in the absence of liver. Amer. J. Physiol. 187, 407–414 (1956).PubMedGoogle Scholar
  102. FORESTIER, J.: La chrysothérapie des polyarthrites. Rhumatologie 1, 66–89 (1949).Google Scholar
  103. FREEMAN, R.B., MÄHER, J. F., SCHREINER, G. E., Mostofi, F.K.: Renal tubular necrosis due to nephrotoxicity of organic mercurial diuretics. Ann. intern. Med. 57, 34–43 (1962b).PubMedGoogle Scholar
  104. FREEMAN, R.B., SHEFF, M. F., Mäher, J. F., Schreiner, G. E.: The blood cerebrospinal fluid barrier in uremia. Ann. intern. Med. 58, 233 –240 (1962a).Google Scholar
  105. FRIEDBERG, V., RÜBENACH, I.: Untersuchungen über die Nierenfunktion während der Narkose und Operation. Klin. Wschr. 35, 974–980 (1957).PubMedCrossRefGoogle Scholar
  106. GABUZA, G.J., GOCKE, T.M., JACKSON, G.G., GRIGSBY, M.E., DEL LOVE, B., Jr., FINLAND, M.: Some effects of antibiotics on nutrition in man. Arch, intern. Med. 101, 476–513 (1958).Google Scholar
  107. GAUERT, W.B., BUSCHMAN, D., PARMLEY, R. T.: Renal function associated with methoxy-flurane anesthesia. S. Afr. med. J. 62, 1587–1490 (1969).Google Scholar
  108. GERHARDT, R. E., KNAUSS, R. F., THYRAM, P. T., LUCHI, R. J., MORRIS, J. J.: Quinidine excretion in aciduria and alkaluria. Ann. intern. Med. 71, 927–933 (1969).PubMedGoogle Scholar
  109. GINGELL, J. C., CHISHOLM, G. D.: Renal tissue levels of gentamicin and a dose schedule in renal impairment. Ther. Umsch. suppl. 1, 38–42 (1969).Google Scholar
  110. GINGELL, J. C., WATERWORTH, P. M.: Dose of gentamicin in patients with normal renal function and renal impairment. Brit. med. J. 1968II, 19–22.Google Scholar
  111. GIROMINI, M., WASEM, R., MERIER, G., FABRE, J.: Influence de l’anurîe et des hémodialyses sur le comportement des antibiotiques. Praxis 58, 1181–1187 (1969).PubMedGoogle Scholar
  112. GLAZKO, A.J., DILL, W.A., WOLFF, L.M.: Observations on the metabolic disposition of chloramphenicol in the rat. J. Pharmacol, exp. Ther. 104, 452–455 (1952).Google Scholar
  113. GLOGNER, P., LANGE, H., PFAB, R.: Tolbutamidstoffwechsel bei Niereninsuffizienz. Med. Welt 52, 2876–2878 (1968).PubMedGoogle Scholar
  114. GOFF, J.B., SCHLEGEL, J. U., O’DELL, R.M.: Urinary excretion of nalidixic acid, sulfamethizole, and nitrofurantoin in patients with reduced renal function. J. Urol. 99, 371–375 (1968).PubMedGoogle Scholar
  115. GOODMAN, L.S., GILMAN, A.: The pharmacological basis of therapeutics. 4th edition. New York: McMillan 1970.Google Scholar
  116. GOODWIN, N.J., FRIEDMAN, E.A.: The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum colistimethate levels. Ann. intern. Med. 66, 984–994 (1968).Google Scholar
  117. GRAHAME-SMITH, D. G., EVEREST, M. S.: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Brit. med. J. 1969I, 286–289.Google Scholar
  118. GREENBERG, P. A., SANFORD, J. P.: Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Ann. intern. Med. 68, 465–479 (1967).Google Scholar
  119. GSELL, O., DUBACH, U. C, Raillard-Peucker, U.: Phenacetine Abusus und Nierenleiden. Dtsch. med. Wschr. 93, 101–108 (1968).Google Scholar
  120. HABIF, D.V., PAPPER, E. M., FITZPATRICK, H. F., LOWRANCE, P., SMYTHE, C., BRADLEY, S. E.: The renal and hepatic blood flow, glomerular filtration rate and urinary output of electrolytes during cyclopropane, ether and thiopental anesthesia, operation and the immediate post-operative period. Surgery 30, 241–255 (1951).PubMedGoogle Scholar
  121. HAMBURGER, J.: Résultats de 45 homotransplantations rénales humaines. In: Actualités néphrologiques de l’Hôpital Necker, p. 83. Paris: Flammarion 1965.Google Scholar
  122. HENDERSON, E. S., ADAMSON, R.H., OLIVERIO, V. T.: The metabolic fate of tritiated metho¬trexate. II. Absorption and excretion in man. Cancer Res. 25, 1018–1024 (1965).PubMedGoogle Scholar
  123. HEYMAN, A., PATTERSON, J. L., JONES, R.W.: Cerebral circulation and metabolism in uremia. Circulation 1, 558–563 (1951).Google Scholar
  124. HINMAN, A.R., WOLINSKY, E.: Nephrotoxicity associated with the use of cephaloridin. J. Amer. med. Ass. 200, 724–726 (1967).CrossRefGoogle Scholar
  125. HOFFMAN, T. A., CESTERO, R., BULLOCK, W. E.: Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann. intern. Med. 73, 173–178 (1970).PubMedGoogle Scholar
  126. HOPPER, J., Jr., JAWETZ, E., HINMAN, F., Jr.: Polymyxin B in chronic pyelonephritis: observations on the safety of the drug and on its influence on the renal infection. Amer. J. med. Sei. 225, 402–409 (1953).CrossRefGoogle Scholar
  127. HUANG, C.L., KURLAND, A.A.: A quantitative study of chlorpromazine and its sulfoxides in the urine of psychotic patients. Amer. J. Psychiat. 118, 428–437 (1961).PubMedGoogle Scholar
  128. JELLIFFE, R.W.: An improved method of digoxin therapy. Ann. intern. Med. 69, 703–717 (1968).PubMedGoogle Scholar
  129. JELLIFFE, R.W., BUELL, J., KALABA, R., SRIDHAR, R., Rockwell, R., Wagner, J. G.: An improved method of digitoxin therapy. Ann. intern. Med. 72, 453–464 (1970).PubMedGoogle Scholar
  130. JENNE, J.W., MACDONALD, F. M., Mendoza, E.: A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and para-aminosalicylic acid in man. Amer. Rev. resp. Dis. 84, 371–378 (1961).PubMedGoogle Scholar
  131. JUNGERS, P., KLEINKNECHT, D., LOIRAT, P.: Les accidents rénaux de la céphaloridine. Presse méd. 70, 1515–1518 (1969).Google Scholar
  132. KABINS, S.A., COHEN, S.: Cephalothin serum levels in azotemic patient. Antimicrob. Agents Chemother. 4, 207–214 (1964).Google Scholar
  133. KALOWSKI, S., MATHEW, T.H., SINGHNAURA, R., KINCAID-SMITH, P.: Deterioration in renal function in association with co-trimoxazole therapy. Lancet 1973I, 394–397.Google Scholar
  134. KALSER, S.C., KELVINGTON, E. J., RANDOLPH, M.M., Santomenna, D.M.: Drug metabolism in hypothermia. I. Biliary excretion of C14 atropine metabolites in the intact and neph- rectomized rat. J. Pharmacol, exp. Ther. 147, 252–259 (1965).Google Scholar
  135. KATZ, J., SARMUB, L., KOREUTZ, COHN, R.: Anesthesic considerations for renal transplant. Anesthesia and Analgesia. Curr. Res. 48, 609–613 (1967).Google Scholar
  136. KEBERLE, H., HOFFMANN, K., BERNHARD, K.: The metabolism of glutethimide (Doriden). Experientia (Basel) 18, 105–111 (1962).CrossRefGoogle Scholar
  137. KESSLER, R.H.: Clinical pharmacology of chlorothiazide compounds. Clin. Pharmacol. Ther. 3, 109–118 (1962).PubMedGoogle Scholar
  138. KIND, A.C., TUPAS, T.E., STANDIFORD, H.C., KIRB, W.M.M.: Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch, intern. Med. 125, 685–690 (1970).Google Scholar
  139. KLEINKNECHT, D., BABINET, P., GANEVAL, D. et al.: La 5-fluorocytosine dans le traitement des candidoses avec insuffisance rénale aiguë. J. Urol. Néphrol. 79, 753–755 (1973).Google Scholar
  140. KOCH-WESER, J., SIDEL, V.W., FEDERMAN, E.B., KANAREK, P., FINER, D.C., EATON, A.E.: Adverse effects of sodium colistimethate. Ann. intern. Med. 72, 857–868 (1970).PubMedGoogle Scholar
  141. KOECHLIN, B. A., SCHWARTZ, M. A., KROL, G., OBERHANSLI, W.: The metabolic fate of Ci4-labeËed chlordiazepoxide in man, in the dog, and in the rat. J. Pharmacol, exp. Ther. 145, 399–411 (1965).Google Scholar
  142. KOIDE, M., Waüd, B.E.: Serum potassium concentration after succinylcholine in patients with renal failure. Anesthesiology 36, 142–145 (1972).PubMedCrossRefGoogle Scholar
  143. KOPPEL, M.H., Shinaberger, J. H., Massry, S. G., Popovtzer, M. M., Coburn, J.W.: Hypercalcemic response to hydrochlorothiazide in uremia. Clin. Res. 17, 435 (1969).Google Scholar
  144. KRACKHARDT, H., von: Blutspiegel und Ausscheidung des Cycloserins bei länger dauernder Medikation. Schweiz. Z. Tuberk. 17, 403–416 (1960).Google Scholar
  145. KRAMER, P., WILLMS, B., HORENKAMP, J., SCHELER, F.: Blutspiegelkinetik und renal clearance von H3-Peruvosid. Klin. Wschr. 47, 1157–1166 (1969).PubMedCrossRefGoogle Scholar
  146. KRüGER-THIEMER, E.: Dosage schedule and pharmacokinetics in chemotherapy. J. Amer, pharm. Ass. (Sc. ed.) 49, 311–313 (1960).CrossRefGoogle Scholar
  147. KRÜGER-THIEMER, E.: Pharmacokinetics and dose concentration relationships. Proc. 3rd Intern. Pharmacological Meeting. Vol. 7. Physico-chemical aspects of drug action, pp. 63–113. New York: Pergamon Press 1968.Google Scholar
  148. KUNIN, C. M.: Analysis of the restrictions imposed by renal failure on antibiotic therapy of pyelonephritis. In: Biology of pyelonephritis, p. 623. London: Churchill, 1960.Google Scholar
  149. Kunin, C. M.: A guide to the use of antibiotics in patients with renal disease. Ann. intern. Med. 67, 151–158 (1967).PubMedGoogle Scholar
  150. KUNIN, C. M.: Atuk, N.: Excretion of cephaloridine and cephalothin in patients with renal impairment. New Engl. J. Med. 274, 654–656 (1966).Google Scholar
  151. KUNIN, C. M.: CHALMERS, T.C., LEEVY, C.M., SEBASTYEN, S.C., Lieber, C.S., Finland, M.: Absorption of orally administered neomycin and kanamycin. New Engl. J. Med. 262, 380–385 (1960).Google Scholar
  152. KUNIN, C. M.: FINKELBERG, Z.: Oral cephalexin and ampicillin: Antimicrobial activity, recovery in urine and persistence in blood of uremic patients. Ann. intern. Med. 72, 349–356 (1970).PubMedGoogle Scholar
  153. KUNIN, C. M., FINLAND, M.: Persistence of antibiotics in blood of patients with acute renal failure. — III. Penicillin, streptomycin, erythromycin, and kanamycin. J. clin. Invest. 38, 1509–1519 (1959a).PubMedCrossRefGoogle Scholar
  154. KUNIN, C. M., FINLAND, M.: Restrictions imposed on antibiotic therapy by renal failure. Arch, intern. Med. 104, 1030–1050 (1959b).Google Scholar
  155. KUNIN, C. M.: GLAZKO, A. J., FINLAND, M.: Persistence of antibiotics in blood of patients with acute renal failure. — II. Chloramphenicol and its metabolites in the blood of patients with severe renal disease or hepatic cirrhosis. J. clin. Invest. 38, 1498–1508 (1959 c).Google Scholar
  156. KUNIN, C. M.: REES, S.B., Merrill, J. P., Finland, M.: Persistence of antibiotics in blood of patients with acute renal failure. — I. Tetracycline and Chlortetracycline. J. clin. Invest. 38, 1487–1497 (1959d).PubMedCrossRefGoogle Scholar
  157. KUZUCU, E. Y.: Methoxyflurane, tetracycline, and renal failure. J. Amer. med. Ass. 211, 1162–1164 (1970).CrossRefGoogle Scholar
  158. LAHRTZ, H., REINOLD, N.M., van ZWIETEN, P. A.: Serum concentration and urinary excretion of 3H ouabain in patients suffering from Hver or kidney diseases. Pharmacol. Clin. 1, 114–118 (1969).CrossRefGoogle Scholar
  159. LAMBERT, C. R.: Nouveau traitement des schistosomiases et de l’amibiase, le Ciba 32.644-Ba (Ambilhar.). Acta trop. 23, 1–80 (1966).PubMedGoogle Scholar
  160. LANGECKER, H., WITZGALL, H.: Beziehung zwischen Stoffwechselvorgängen und renalen Ausscheidungsmodus bei Sulfonamide. Klin. Wschr. 40, 32–34 (1962).PubMedCrossRefGoogle Scholar
  161. LAPIDES, J., ALKEMA, H.D., MCDONALD, L. P., SLOAN, J.B., Zierdt, D., Herwig, K., Petrone, A.F.: Correlation of urinary output with serum and spinal fluid mannitol levels in normal and azotemic patients. J. Urol. 99, 662–669 (1968).PubMedGoogle Scholar
  162. LARENG, Bausillon, Caillard: Insuffisance rénale et anesthésie. Anesth. Anaig. 27, 37–80 (1970).Google Scholar
  163. LASSEN, J.B., NIELSEN, D.E.: Investigations into the diuretic effect and elimination of triamterene. Acta Pharmacol. Toxicol. 20, 309–316 (1963).Google Scholar
  164. LAST, P.M., SHERLOCK, S.: Systemic absorption or orally administered neomycin in liver disease. New Engl. J. Med. 262, 385–389 (1960).Google Scholar
  165. LAWRASON, F.D., ALPERT, E., MOHR, F.L., MCMAHON, F. G.: Ulcerative obstructive lesions of the small intestine. J. Amer. med. Ass. 191, 641–644 (1965).CrossRefGoogle Scholar
  166. LHERMITTE, F., FRITEL, D., CAMBIER, J., MARTEAU, R., Gautier, J. C, Nocton, F.: Poly¬névrite au cours de traitements par la nitrofurantoïne. Presse méd. 71, 767–770 (1963).PubMedGoogle Scholar
  167. LINBERG, A. A., NILSSON, L.H., BUCHT, H., KALLINGS, L.O.: Concentration of chloramphenicol in the urine and blood in relation to renal function. Brit. med. J. 1966II, 724–728 (1966).Google Scholar
  168. LINDHOLM, D.D., MURRAY, J.S.: Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. New Engl. J. Med. 274, 1047–1051 (1966).Google Scholar
  169. LINDHOLMER, B., NAYM, E., RAF, L.: Nonspecific stenosing ulceration of small bowel. Acta chir. scand. 128, 310–311 (1964).PubMedGoogle Scholar
  170. LINE, D.H., POOLE, G..W, WATERWORTH, P.M.: Serum streptomycin levels and dizziness. Tubercle (Lond.) 51, 76–81 (1970).Google Scholar
  171. LINQUIST, J.A., SIDDIQUI, J. Y., SMITH, I.M.: Cephalexin in patients with renal disease. New Engl. J. Med. 283, 720–723 (1970).Google Scholar
  172. LIPMANN, R. W., MARTI, H. U.: Effect of renal function on excretion of sulfadimetine given in small doses for urinary infection. J. Urol. 70, 548–551 (1953).Google Scholar
  173. LISSAC, J., AMIEL, C., MOREL-MAROGER, L., MIGNON, F.: Néphrite interstitielle aiguë due à une intoxication massive et prolongée par le méthane sulfonate de Colistine. J. Urol. Néphrol. 70, 789–797 (1964).Google Scholar
  174. LOCKERT, S.: Haemodialysis in the treatment of acute poisoning. Proc. roy. Soc. Med. 63, 427–430 (1970).Google Scholar
  175. LOURIA, D.B.: Some aspect of the absorption, distribution and excretion of amphotericin B in man. Antibiot. Med. CHn. Ther. 5, 295–301 (1958).Google Scholar
  176. MANIGARD, G., AUZEPY, P., LARDY, C.: Un cas d’intolérance grave au cours d’un traitement par la phénindione: mesures préventives à prendre. Sem. Hôp. Paris 44, 3217–3222 (1968).Google Scholar
  177. MANNHART, M., DETTLI, L., SPRING, P.: Die Elimination des Doxyzyklins und ihre Beeinflussung durch die Hämodialyse bei anurischen Patienten. Schweiz, med. Wschr. 101, 123–127 (1971).Google Scholar
  178. MARCUS, F.I., PETERSON, A., SALEI, A.: The metabolism of tritiated digoxin in renal insufficiency in dogs and man. J. Pharmacol, exp. Ther. 152, 372–382 (1966).Google Scholar
  179. MAREN, T.H., MAYER, E., WADSWORTH, B. C.: Carbonic anhydrase inhibition. I. The pharmacology of Diamox. Bull. Hopkins Hosp. 95, 199–243 (1954).Google Scholar
  180. MARK, L.C., KAYDEN, H. J., STEEL, J.M., COOPER, J. R., Berlin, I., Rovenstein, E.A., Brodie, B.B.: The physiologic disposition and cardiac effects of procaine amide. J. Pharmacol, exp. Ther. 102, 5–15 (1951).Google Scholar
  181. MASCITELLI-CORIANDOLI, E.: In: Mueckter, H.: Zur Pharmakologie der basischen Streptomyces-Antibiotika. Antibiot. Chemother. 9, 83–114 (1961).Google Scholar
  182. MASCITELLI-CORIANDOLI, E., BOLDRINI, R., CITTERIO, C.: Abnahme des Gehaltes von Coenzym A in Leber und Nieren bei experimenteller Nephrose. Naturwissenschaften 45, 442–456 (1958).CrossRefGoogle Scholar
  183. MAST, W.H.: Neuropathy due to furaltaden. New Engl. J. Med. 263, 963 (1960).Google Scholar
  184. MATHOG, R.H., KLEIN, W.J.: Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia. New Engl. J. Med. 280, 1223–1224 (1969).Google Scholar
  185. MATZ, G. J., NANTON, R.F.: Ototoxic drugs and poor renal function. J. Amer. med. Ass. 208, 2119 (1968).CrossRefGoogle Scholar
  186. MA WER, G. E., KNOWLES, B.R., LUCAS, S. B., STIRLAND, R.M.: Computer-assisted precribing of kanamycin for patients with renal insufficiency. Lancet 1972I, 12–15 (1972a).Google Scholar
  187. MAWER, G.E., LUCAS, S.B.: Normogramfor kanamycin dosage. Lancet 1972II, 45 (1972b).Google Scholar
  188. MCCHESNEY, E. W., FROELICH, E. J., LESHER, G.Y.: Nalidixic acid. Absorption, excretion and metabolism. Toxic, appl. Pharmacol. 6, 292–309 (1964).Google Scholar
  189. MCCLOSCKEY, R.V., HAYES, C.P.: Plasma levels of dicloxacillin in oliguric patients and the effect of hemodialysis. Antimicrob. Agents Chemother. 7, 770–772 (1967).Google Scholar
  190. MCHENRY, M.C., GAVAN, T.L., GIFFORD, R. W.: Gentamicin dosages for renal insufficiency: adjustments based on endogenous creatinine clearance and serum creatinine clearance and serum creatinine concentration. Ann. intern. Med. 74, 192–197 (1971).PubMedGoogle Scholar
  191. McKay, D.N., KAYE, D.: Serum concentrations of Colistin in patients with normal and impaired renal function. New Engl. J. Med. 270, 394–397 (1964).Google Scholar
  192. MELLETT, L. B., HODGSON, P. E., WOODS, L. A.: Absorption and fate of C14-labeled thio-TEPA in humans and dogs. J. Lab. clin. Med. 60, 818–825 (1962).PubMedGoogle Scholar
  193. MELLK, H.M., LETTERI, J.M., DURANTE, P.: Diphenylhydantoin metabolism in chronic uremia. Ann. intern. Med. 72, 801 (1970).Google Scholar
  194. MERIER, G., RUDHARDT, M., HERRERA, A., WASEM, R., FABRE, J.: Le comportement de l’oxytétracycline en cas d’insuffisance rénale. Schweiz, med. Wschr. 100, 1442–1446 (1970).Google Scholar
  195. MICHAEL, A. F., VERNIER, R.L., DRUMMOND, K. N.: Immunosuppressive therapy of chronic renal disease. New Engl. J. Med. 276, 817–828 (1967).Google Scholar
  196. MILES, B.E., De WARDENER, H. E., CHURCHILL-DAVIDSON, H. C., WYLIE, W.D.: Effect on renal circulation of pentamethonium bromid anesthesia. Clin. Sei. 11, 73–79 (1952).Google Scholar
  197. MILLER, R.D., BATES, J.H.: Amphotericin B toxicity. Ann. intern. Med. 71, 1089–1095 (1969).PubMedGoogle Scholar
  198. MILLER, R.D., WAY, W.L., HAMILTON, W. H., LAZZER, R.B.: Succinylcholine-induced hyperkaliemia in patients with renal failure. Anesthesiology 36, 138–141 (1972).PubMedCrossRefGoogle Scholar
  199. MILNE, M. D., ROWE, G. G., SOMERS, K., MUEHRCKE, R. C., Crawford, M. A.: Observations on the pharmacology of mecamylamine. Clin. Sei. 18, 599–614 (1957).Google Scholar
  200. MOLLARET, P., MÖNS ALLIER, J. F., POCIDALO, J. J., Rapin, M.: Etudes sur l’intoxication barbiturique aiguë. — I. Les effets des variations de l’équilibre acide-basique sur la répartition du phénobarbital dans l’organisme du chien néphrectomisé. Rev. franç. Etudes clin. Biol. 4, 575–581 (1959).PubMedGoogle Scholar
  201. MORGENSTERN, L., FREILICH, M., PANISH, J. F.: The circumferantial smallbowel ulcer. J. Amer. med. Ass. 191, 637–640 (1965).CrossRefGoogle Scholar
  202. MUECKTER, H.: Zur Pharmakologie des basischen Streptomyces-Antibiotika. Antib. Chemother. 9, 83–114 (1961).Google Scholar
  203. MURPHY, K.J.: Uraemic accentuation of chlorpromazine pigmentation. Med. J. Austr. 2, 1228–1229 (1966).Google Scholar
  204. NOWELL, P. T., SCOTT, C. A., WILSON, A.: Hydrolisis of neostigmine by plasmacholinesterase. Brit. J. Pharmacol. 18, 498–502 (1962).Google Scholar
  205. O’BRIEN, J.P., SHARP, A.R., Jr.: The influence of renal disease on the insulin (I131) disappearance curve in man. Metabolism 16, 76–83 (1967).PubMedCrossRefGoogle Scholar
  206. Odar-Cederlöf, I., Lunde, P., SJÖQVIST, F.: Abnormal pharmacokinetics of phenytoin in a patient with uremia. Lancet 1970II, 831–832.Google Scholar
  207. OGG, C.S., TOSELAND, P. A., CAMERON, J.S.: Pulmonary tuberculosis, in patient on hemodialysis. Brit. med. J. 1968II, 283–284.Google Scholar
  208. O’GRADY, F.: Antibiotics in renal failure. Brit. med. Bull. 27, 142–147 (1971).Google Scholar
  209. OKITA, G.T., Talso, P. J., CURRY, J.H., SMITH, F.D., GELLING, E.M.K.: Metabolic fate of radioactive digitoxin in human subjects. J. Pharmacol, exp. Ther. 115, 371–379 (1955).Google Scholar
  210. OLSEN, S.: The brain in uremia. Acta psychiat. scand. 36, Suppl. 156, 1–128 (1961).Google Scholar
  211. ONESTI, G., BOCK, K.D., HEIMSOTH, V.: Clonidine: a new antihypertensive agent. Amer. J. Cardiol. 28, 74–83 (1971).PubMedCrossRefGoogle Scholar
  212. ORME, B.M., CUTLER, R.E.: The relationship between kanamycin pharmacokinetics, distribution and renal function. Clin. Pharmacol. Ther. 10, 543–550 (1969).PubMedGoogle Scholar
  213. OTTO, G.F., MAREN, T.H., BROWN, H.W.: Blood levels and excretion rates of antimony in persons receiving trivalent antimonials. Amer. J. Hyg. 45, 193–211 (1947).Google Scholar
  214. PAPAC, R., CREASY, W.A., CALABRESI, P., WELCH, A.D.: Clinical and pharmacological studies with I-B-arabinofuranosylcytosine (cytosine arabinoside). Proc. Amer. Ass. Cancer Res. 6, 50 (1965).Google Scholar
  215. PAPPER, E.M.: Renal function during general anesthesis and operation. J. Amer. med. Ass. 152, 1686–1689 (1953).CrossRefGoogle Scholar
  216. PAUL, M. F., PAUL, H. E., KOPKO, F., BRYSON, M. J., Harrington, C.: Inhibition by furacin of citrate formation in testis preparation. J. biol. Chem. 208, 491–497 (1954).Google Scholar
  217. PAYET, M., SANKALE, M.: Hyperazotémies transitoires consécutives au traitement de la trypanosomiase humaine africaine avec des diamidines. Bull. Soc. path. Exot. 53, 690–696 (1960).Google Scholar
  218. PEETS, E.A., SWEENEY, W. M., PLACE, V. A., BUYSKE, D.A.: The absorption, excretion, and metabolic fate of ethambutol in man. Amer. Rev. Resp. Dis. 91, 51–58 (1965).PubMedGoogle Scholar
  219. PERKINS, P. L., SMITH, E. J., SASLAW, S.: Cephalothin and cephaloridine: comparative pharmacodynamics in chronic uremia. Amer. J. Med. Sei. 257, 116–124 (1969).CrossRefGoogle Scholar
  220. PETITPIERRE, B., FABRE, J.: Effet de l’insuffisance rénale sur l’action hypoglycémiante des sulfonylurées. Cinétique de la chlorpropamide en cas de néphropathie. Schweiz, med. Wschr. 102, 570–578 (1972).Google Scholar
  221. PETITPIERRE, B., PERRIN, L., RUDHARDT, M., HERRERA, A., FABRE, J.: Behavior of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int. J. Pharmacol. 6, 120–124 (1972).Google Scholar
  222. PEZZI, P. I., FROBESE, A.S., GREENBERG, S. R.: Methoxyflurane and renal toxicity. Lancet 1966I, 823.Google Scholar
  223. PILLAY, V.K.G., SCHWARTZ, F.D., AIMI, K.: Transient and permanent deafness following treatment with ethacrynic acid in renal failure. Lancet 1969I, 77–79.Google Scholar
  224. PLACE, V.A., THOMAS, J.P.: Clinical pharmacology of ethambutol. Amer. Rev. resp. Dis. 87, 901–904(1963).Google Scholar
  225. PLAUT, M. E., O’CONNELL, C. J., PABICO, R. C, Davidson, D.: Penicillin handling in normal and azotemic patients. J. Lab. clin. Med. 74, 12–18 (1969).PubMedGoogle Scholar
  226. PLETKA, P., COHEN, S.L., KENYON, J. R., SNELL, M.: Cadaveric renal transplantation. An analysis of 65 cases. Lancet 1969I, 1–6 (1969).Google Scholar
  227. POHL, J.E., THURSTON, H.: Use of diazoxide in hypertension with renal failure. Brit. med. J. 1971IV, 142–145 (1972).Google Scholar
  228. POLLAK, V. E.: Anticoagulants in the treatment of renal disease. Ann. intern. Med. 73, 334–335 (1970).PubMedGoogle Scholar
  229. POWELL, J.N.: Suxamethonium-induced hyperkaliemia in a uraemic patient. Brit. J. Anesth. 42, 806–807 (1970).CrossRefGoogle Scholar
  230. PRESCOTT, L.F.: Effects of acetylsalicyclic acid, phenacetin, paracetamol and caffeine on renal tubular epithelium. Lancet 1965II, 91–96.Google Scholar
  231. PRESCOTT, L.F.: The metabolism of phenacetin in patients with renal diseases. Clin. Pharmacol. Ther. 10, 383–394 (1969).PubMedGoogle Scholar
  232. RAABLAUF, J., DUBACH, U. C.: Dose-dependant change in the pattern of phenacetin metabolism in man and its possible significance in analgesic nephropathy. Klin. Wschr. 47, 1286–1287 (1969).CrossRefGoogle Scholar
  233. RABINOWITZ, P., FRIEDMAN, I. S.: Drug-induced lactation in uremia. J. clin. Endoer. 21, 1489–1493 (1961).CrossRefGoogle Scholar
  234. RABKIN, R., SIMON, N.M., STEINER, S., COLWELL, J.A.: Effect of renal disease on renal uptake and excretion of insulin in man. New Engl. J. Med. 282, 182–187 (1970).Google Scholar
  235. RAHN, K.H., DAYTON, P. G.: Studies on the metabolism of guanethidine in hypertensive patients. Biochem. Pharmacol. 18, 1809–1916 (1969).PubMedCrossRefGoogle Scholar
  236. REGAMEY, C., HUMAIR, L.: Pharmacokinetics of cephalexin in renal insufficiency. Postgrad, med. J. 47, suppl., 69–78 (1971).Google Scholar
  237. REIDENBERG, M.M.: Renal function and drug action. Philadelphia-London-Toronto: W. B. Saunders Comp. 1971.Google Scholar
  238. REIDENBERG, M.M., KOSTENBAUDER, H., ADAMS, W.: Rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients. Metabolism 18, 209–123 (1969).PubMedCrossRefGoogle Scholar
  239. REIDENBERG, M.M., ODAR-CEDERLÖF, I., VON BAHR, C., BORGA, O., SJÖQVIT, F.: Protein binding of diphenyl-hydantoin and desmethylimipramine in plasma from patients with poor renal function. New Engl. J. Med. 285, 265–267 (1971).Google Scholar
  240. REINARZ, J.A., MCINTOSH, D. A.: Lincomycin excretion in patients with normal renal function, severe azotemia, and with hemodialysis and peritoneal dialysis. Antimicrob. Agents Chemother. 5, 232–238 (1965).PubMedGoogle Scholar
  241. REUBI, F.: Blutspiegel, Ausscheidung und Dosierung von N-pyrrolidino-methyltetracyclin (PMT, Reverin) bei Nierenkranken. Klin. Wschr. 45, 133–137 (1967).PubMedCrossRefGoogle Scholar
  242. REUBI, F., COTTIER, P. T.: Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretic. Circulation 23, 200–210 (1961).PubMedGoogle Scholar
  243. REUBI, F., MÜNGER, C.: Renale and extrarenale Ausscheidung von N-pyrroHdino-methyltetracyclin (Reverin) bei Patienten mit normaler und eingeschränkter Nierenfunktion. Pharmacol. Clin. 1, 8–18 (1968).CrossRefGoogle Scholar
  244. REUBI, F., VORBURGER, C.: Renale und extrarenale Ausscheidung von Ampicillin bei Patienten mit normaler und eingeschränkter Nierenfunktion. Pharmacol. Clin. 1, 192–202 (1969).CrossRefGoogle Scholar
  245. REUBI, F., COTTIER, P. T., BÜTIKOFER, E.: A comparison of the short-term and long-term haemodynamic effects of antihypertensive therapy. In Catapress in Hypertension, pp. 113–136. London: Conolly and Butterworths 1970.Google Scholar
  246. RICHARDS, R.K., TAYLOR, J. D., KUETER, K.E.: Effect of nephrectomy on the duration of sleep following administration of thiopental and hexobarbital. J. Pharmacol, exp. Ther. 108, 461–473 (1953).Google Scholar
  247. RICHARDSON, J. A., DERROW, A.M., BORCHARDT, K. A.: Therapy with amphotericin B of Candida septicemia in the presence of acute renal failure. Invest. Urol. 8, 247–250 (1968).Google Scholar
  248. RICHET, G., ARDAILOU, R., FILLASTRE, J.P., BLAISE, P.: Sécrétion gastrique de Furémique. Rev. franç. Etude clin. Biol. 10, 180–190 (1965).Google Scholar
  249. RICHET, G., ARDAILOU, R., SULTAN, Y.: Accidents neuro-psychiques chez des urémiques chroniques traités par le méthane-suifonate de Colistine. Bull. Mém. Soc. méd. Hôp. Paris 113, 1199–1205 (1962).PubMedGoogle Scholar
  250. RICHET, G., AUROUSSEAU, M., EMMERICH: Toxicité du méthane sulfonate de Colistine chez le rat en réduction néphronique. In: Richet, G., Fabre, J., de Freudenreich, J., Podevin, R.: La tolérance médicamenteuse au cours de l’insuffisance rénale, pp. 12–17. Paris: Masson 1966a.Google Scholar
  251. RICHET, G., FABRE, J., de FREUDENREICH, J., PODEVIN, R.: La tolérance médicamenteuse au cours de l’insuffisance rénale. Paris: Masson 1966b; and J. Urol. Néphrol. 72, 257–302 (1966b).Google Scholar
  252. RICHET, G., VACHON, F.: Les troubles neuro-psychiques de l’urémie chronique. Bull. Mém. Soc. méd. Hôp. Paris 116, 1253–1272 (1965).PubMedGoogle Scholar
  253. RIEDER, J., FERNEX, M., SCHWARTZ, D.E.: Pharmacokinetic data on the combination sulfamethoxasole plus trimethoprim in patients with renal impairment. Int. Congr. Chemother. 7, A-l/29 (1971).Google Scholar
  254. RIFF, L.J., JACKSON, G. G.: Pharmacology of gentamicin in man. J. infect. Dis. 124 (suppl.), 98–105 (1971).CrossRefGoogle Scholar
  255. ROELSEN, E.: Polyneuritis after nitrofurantoin therapy. Acta med. scand. 175, 145–154 (1964).PubMedCrossRefGoogle Scholar
  256. ROGERS, E.W.: Excretion of piperazine salts in urine. Brit. med. J. 1958I, 136–137.Google Scholar
  257. ROLLY, G., VERSCHRAEGEN, R.: L’anesthésie pour la transplantation rénale. Expérience de 29 cas de transplantation avec des reins de cadavre. Anesth. Analg. Réan. 28, 355–361 (1969).Google Scholar
  258. ROSSUM, J.M.Van: Pharmacokinetics of accumulation. J. pharm. Sei. 57, 2162–2165 (1968).CrossRefGoogle Scholar
  259. ROTH, F., WÜTHRICH, H.: The clinical importance of hyperkaliema following suxamethoni¬um administration. Brit. J. Anesth. 41, 311–316 (1969).CrossRefGoogle Scholar
  260. SACHS, J., GEER, T., NOELL, P., KUNIN, C. M.: Effect of renal function on urinary recovery of orally administered nitrofurantoin. New Engl. J. Med. 278, 1032–1035 (1968).Google Scholar
  261. SACHS, J., HENDERSON, R.R.: Use of bishydroxycoumarin (Dicumarol) in the presence of impaired renal function. J. Amer. med. Ass. 148, 839–841 (1952).CrossRefGoogle Scholar
  262. SCHEINBERG, G.: Effects of uremia on cerebral blood flow and metabolism. Neurology 4, 101–105 (1954).PubMedGoogle Scholar
  263. SCHEITLIN, W., JEANNERET, P.: Über akute Nierenschädigungen unter Phenylbutazon-therapie. Schweiz, med. Wschr. 87, 881–885 (1957).Google Scholar
  264. SCHELER, F.Von, WIGGER, W., HOFFLER, D., QUELLHORST, E.: Steigerung der Digitalistoxizität bei eingeschränkter Nierenfunktion. Dtsch. med. Wschr. 90, 1614–1620 (1965).Google Scholar
  265. SCHEINER, G.E., MÄHER, J.F.: Toxic nephropathy. Amer. J. Med. 38, 409–449 (1965).CrossRefGoogle Scholar
  266. SCHEINER, W. J., BECKER, E.L.: Acute transient hearing loss after ethacrynic acid therapy. Arch, intern. Med. 117, 715–717 (1966).Google Scholar
  267. SCHULTZ, J. C, ADAMSON, J. S., WORKMAN, W. W., NORMAN, T.D.: Fatal liver disease after intravenous administration of tetracycline in high dosage. New Engl. J. Med. 269, 999–1004 (1963).Google Scholar
  268. SCHWARTZ, G.H., DAVID, D.S., RIGGIO, R.R., STENGEL, K.H., RUBIN, A.L.: Ototoxicity induced by Furosemid. New Engl. J. Med. 282, 1413–1414 (1970).Google Scholar
  269. SELLERS, E.M., KOCH-WESER, J.: Protein binding and vascular activity of diazoxide. New Engl. J. Med. 281, 1141–1145 (1969).Google Scholar
  270. SELYE, H., PRIORESCHI, P., CANTIN, M.: Factors that determine the production of cardiovascular and renal lesions by polymyxin. Antibiot. Chemother. 11, 12–25 (1961).PubMedGoogle Scholar
  271. SHAND, D.S., NUCKOLS, E.M., DATES, J. A.: Plasma propranolol levels in adults. With observations in four children. Clin. Pharmacol. Ther. 11, 112–120 (1970).PubMedGoogle Scholar
  272. SHILS, M.E.: Renal disease and the metabolic effects of tetracycline. Ann. intern. Med. 58, 389–408 (1963).PubMedGoogle Scholar
  273. SIMON, N.M., del GRECO, F., DIETZ, A.A., Rubinstein, H. M.: Serum Cholinesterase deficiency in renal failure. Trans. Amer, Soc. artif. intern. Organs 15, 328–331 (1969).Google Scholar
  274. SMITH, C. C., IHRIG, J.: Persistent excretion of pyrimethamine following oral administration. Amer. J. trop. Med. 8, 60–62 (1959).PubMedGoogle Scholar
  275. SMITH, J. W., SEIDL, L.G., CLUFF, L.E.: Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility. Ann. intern. Med. 65, 629–640 (1966).Google Scholar
  276. SMITH, T.W., BUTLER, Y. P., HABER, P.: Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. New Engl. J. Med. 281, 1212–1216 (1969).Google Scholar
  277. SPRING, P.: The pharmacokinetics of Rimactane in patients with impaired liver and kidney function. Symposium on Rimactane, pp. 32–34. Bâie: Ciba 1968.Google Scholar
  278. SPÜHLER, P., ZOLLINGER, H.U.: Die chronische interstitielle Nephritis. Z. klin. Med. 151, 1–50 (1963).Google Scholar
  279. STAMEY, T.A., NEMOY, N. J., HIGGINS, M.: The clinical use of nalidixic acid. Invest. Urol. 6, 582–592 (1969).PubMedGoogle Scholar
  280. STARZL, T.E.: Experience in renal transplantation, p. 180 and 360. Philadelphia-London-Toronto: Saunders 1964.Google Scholar
  281. STRUNIN, L.: Some aspects of anesthesia for renal homotransplantation. Brit. J. Anaesth. 38, 812–822 (1966).PubMedCrossRefGoogle Scholar
  282. SWINYARD, W. A., WEAVER, L.C., GOODMAN, L. S.: Effect of liver injury and nephrectomy on the anticonvulsivant activity of clinically useful hydantoins. J. Pharmacol, exp. Ther. 104, 309–316 (1952).Google Scholar
  283. TAVERNIER, M., DUBOUCHET, N., VAYSSE, M.I.: Problèmes d’anesthésie et de réanimation peropératoire posés par la transplantation rénale chez l’homme. Anesth. Analg. Réan. 22, 129–137 (1965).Google Scholar
  284. TIFFENEAU, M., LEVY, J., BROUN, D.: Influence des variations de la réserve alcaline et du pH sur quelques actions pharmacodynamiques centrales ou périphériques. Arch. int. Pharmacodyn. 38, 463–467 (1930).Google Scholar
  285. TOBIAN, L., BINION, J.: Effect of deficiency of renal tissue with or without resulting hypertension on the electrolyte composition of brain and skeletal muscle. Amer. J. Physiol. 178, 233–236 (1954).PubMedGoogle Scholar
  286. TONNESEN, M.: The excretion of atropine and allied alkaloids in urine. Acta pharmacol. toxicol. 6, 147–164 (1950).CrossRefGoogle Scholar
  287. TOURKANTONIS, A., FRIEDRICH, H., HEINZE, V.: Ampicillin-Nebenwirkung bei Patienten mit Niereninsuffizienz. Med. Klin. 66, 1154–1161 (1971).PubMedGoogle Scholar
  288. TOUSSAINT, C., BRAUMAN, J., SMULDERS, J., LAMBERT, P. P.: Anurie mortelle par phénylbutazone. Livre jubilaire du Pr P. Govaerts, p. 86. Bruxelles: Imprimerie médicale et scientifique 1955.Google Scholar
  289. TRAEGER, J., ZECH, P., TOUBOUL, P.: Les complications rénales toxi-allergiques des traitements anticoagulants par la phenyl-indane-dione. Thérapie 23, 511 (1968).PubMedGoogle Scholar
  290. UEDA, H., SAKURAI, T., OTA, M., NAKAJIMA, A., KAMII, K., MAEZAWA, H.: Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis and renal disease. Diabetes 12, 414–419 (1963).PubMedGoogle Scholar
  291. UPDIKE, S. J., HARRINGTON, A. R.: Acute diabetic keto-acidosis — a complication of intravenous diazoxide treatment for refractory hypertension. New Engl. J. Med. 280, 768 (1969).Google Scholar
  292. VECSEI, P., KEMENY, V.: The effect of experimental uremia on the disappearance of prednisolone in white rats. Med. exper. 8, 35–38 (1963).Google Scholar
  293. VERBECKMOES, R.: Etude de la tolérance de l’acide nalidixique chez les insuffisants rénaux. J. Urol. Néphrol. 72, 303–305 (1966).Google Scholar
  294. VIC-DUPONT, MONSALLIER, J. F., VACHON, F., ROCHANT, H.: Incidences rénales des traitements parle méthane-suifonate de colistine. Bull. Mém. Soc. méd. Hôp. Paris 116, 25–37 (1965).Google Scholar
  295. VREE, T. B.: Kinetics of distribution and metabolism of amphetamines and phentermines in man and animals. Intern. Congress Pharmacol. 4, 453 (1969).Google Scholar
  296. WAY, E.L., ADLER, T. K.: The pharmacologic implications of the fate of morphine and its surrogates. Pharm. Rev. 12, 383–446 (1960).PubMedGoogle Scholar
  297. WEINER, I.M., MUDGE, G. H.: Renal tubular mechanisms for excretion of organic acids and bases. Amer. J. Med. 36, 743–762 (1964).PubMedCrossRefGoogle Scholar
  298. WEINSTEIN, L., LERNER, P. I., CHEW, W.H.: Clinical and bacteriologic studies of the effect of “massive” doses of penicillin G on infections caused by gramnegative bacilli. New Engl. J. Med. 271, 525–533 (1964).Google Scholar
  299. WEISS, P., HERSEY, R. M., DUJORNE, C.A., BIANCHINE, J. R.: The metabolism of amiloridine hydrochloride in man. Clin. Pharmacol. Ther. 10, 401–406 (1969).PubMedGoogle Scholar
  300. WERNER, C. A., ADAMS, C., DUBOIS, R.: Absorption and excretion of viomycin in humans. Proc. Soc. exp. Biol. (N. Y.) 76, 292–295 (1951).Google Scholar
  301. WHALLEY, P. J., ADAMS, R.H., COMBES, B.: Tetracyclin toxicity in pregnancy. Liver and pancreatic dysfunction. J. Amer. med. Ass. 189, 357–362 (1964).CrossRefGoogle Scholar
  302. WILFERT, J.N., BURKE, J.P., BLOOMER, H.A., SMITH, C.B.: Renal insufficiency associated with gentamicin therapy. J. infect. Dis. 124, suppl. S 148–S 153 (1971).Google Scholar
  303. WILLIAMS, O.M., WIMPENNY, J., ASSCHER, A.W.: Renal clearance of sodium sulphadimidine in normal and uraemic subjects. Lancet 1968II, 1058–1060.Google Scholar
  304. WOLINSKI, E., HINES, J.D.: Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. New Engl. J. Med. 268, 759–762 (1962).Google Scholar
  305. WOODRUFF, M.F. A., NOLAN, B., ROBSON, J. S., McDonald, M.K.: Renal transplantation in man. Experience in 35 cases. Lancet 1969I, 6–12.Google Scholar
  306. WOODS, J. W., BLYTHE, W.B.: Management of malignant hypertension complicated by renal insufficiency. New Engl. J. Med. 277, 57–61 (1967).Google Scholar
  307. WRIGHT, W.W., PUTNAM, L.E., WELCH, H.: Novobiocin: serum concentrations and urinary excretion following oral administration in man. Antibiot. Med. 2, 311–316 (1956).PubMedGoogle Scholar
  308. WYANT, S.M.: The anesthesist looks at tissue transplantation: three years’ experience with kidney transplant. Canad. Anaesth. Soc. J. 14, 255–275 (1967).PubMedCrossRefGoogle Scholar
  309. YOUNG, I. M., DEWARDENER, H. E., MILES, B.E.: Mechanism of the renal excretion of methonium compounds. Brit. med. J. 1951II, 1500–1501.Google Scholar
  310. YOW, E.M., MOYER, J.H.: Toxicity of polymyxin B. Arch. intern. 92, 248–257 (1953).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1974

Authors and Affiliations

  • Jean Fabre
  • Irving Ohr

There are no affiliations available

Personalised recommendations